C1B5, a synthetic subdomain peptide of PRKCG, has shown anticancer potential in pancreatic cancer via the activation of T and NK cells in a study investigating the effect of cotreatment with C1B5 and gemcitabine in a pancreatic cancer mouse model [33]. The gene discussed is PRKCG; the disease is familial pancreatic carcinoma.